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Figure 1. Cumulative incidence of grade 3-4 aGVHD among BM (A) and PBSC
recipients (B).
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provide a quantitative measure of physical functioning not
captured by traditional resting parameters. We investi-
gated whether functional capacity predicted mortality af-
ter HCT.
Patients and Methods: Using a prospective design, 409
patients completed a six-minute walk distance test
(6MWD) prior to undergoing HCT. 6MWDs were obtained
within 5 days of transplant admission; carbon monoxide
diffusing capacity (DLCO) and left ventricular ejection frac-
tion (LVEF) were determined within 1 month of admission,
Karnofsky performance status (KPS) was reported imme-
diately prior to admission and hemoglobin (Hgb) was ob-
tained on the day of transplant. Cox proportional hazards
regressionwere used to estimate the risk of mortality due to
relapse or progression of disease (RM), non-relapse mor-
tality (NRM), and overall survival (OS) according to 6MWD
(<400 m versus 400 m) with adjustment for cardiovas-
cular risk factors.
Results: Participant characteristics are presented in the
Table. Mean 6MWD was 404  113 m (range: 71 to 737 m).
Median follow-up was 36 months (range 3 to 61 months).
During this period, 43% patients died (n¼104, NRM). In
univariate analyses, 6MWD predicted NRM (p¼0.025) and
OS (p¼0.028; Figure), but not RM (p¼0.468). Compared
with patients achieving a 6MWD <400 m, the unadjusted
hazard ratio (HR) for NRM and OS was 0.64 (95% CI,
0.44e0.95) and 0.72 (95% CI, 0.53e0.96), respectively for
those achieving 400 m. In multivariable analyses, the
relationship between 6MWD and NRM and OS became non-
signiﬁcant after adjustment for KPS, DLCO, and Hgb con-
centration. LVEF did not predict any post-HCT outcomes
(p’s>0.05).
Conclusions: Although 6MWD was not an independent
predictor of post-HCT outcomes, the strong univariate asso-
ciation with NRM and OS suggests further investigation of
alternative measures of physical functioning (e.g., exercise
capacity) are warranted.13
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(aGVHD) after HLA-matched sibling bone marrow (BM)
allogeneic hematopoietic cell transplantation (alloHCT) is
lower in the Japanese than the Caucasians (Blood 2005,
105:1408). However, the impact of race on aGVHD might
differ according to graft source (BM versus peripheral blood
stem cell (PBSC)) in HLA-matched sibling alloHCT. To test this
hypothesis, we analyzed data from the Center for Interna-
tional Blood and Marrow Transplant Research and the Japan
Society for Hematopoietic Cell Transplantation.
Methods: North American Caucasian and Japanese patients
who received their ﬁrst allogeneic BM or PBSC alloHCT from
HLA-matched sibling for acute leukemia in complete remis-
sion or chronic leukemia in chronic or accelerated phase
between 2000 and 2011 were eligible. Patients were 18 - 59
years old, received myeloablative conditioning regimen, and
used cyclosporine or tacrolimus-based GVHD prophylaxis.
Effect of race (Caucasian vs. Japanese), graft source (BM vs.
PBSC), and their interaction on transplant outcomes was
evaluated in the Cox proportional hazards model adjusting
for other signiﬁcant variables.
Results: Median ages of Caucasians and Japanese patients
were 45 and 38 years, respectively. BMwas used in 13% of the
Caucasians, whereas it was used in 53% of the Japanese. Cor-
responding rates of tacrolimus-based GVHD prophylaxis
were 68% and 7%. The cumulative incidence of grade 3-4
aGVHD at 100 days post BM alloHCT was 10% and 6% in the
Caucasians and Japanese, respectively (Figure 1A), and that of
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S35grade 3-4 aGVHD post PBSC alloHCT was 14% and 10% in the
Caucasians and Japanese, respectively (Figure 1B). In
multivariate analysis, the interaction term between race and
graft source was not signiﬁcant in any of the models,
indicating that the impact of race on outcomes does not
differ according to graft source. The risk of grade 3-4 aGVHD
was signiﬁcantly lower in Japanese compared to Caucasians
(HR 0.74, 95% CI 0.57-0.96), which resulted in lower risk of
non-relapse mortality (NRM) in Japanese compared to
Caucasian patients (HR 0.69, 95% CI 0.54-0.89). The risk of
relapse was also lower in Japanese compared to Caucasian
patients (HR 0.75, 95% CI 0.63-0.89). Lower risk of NRM and
relapse resulted in lower overall mortality rates in Japanese
compared to Caucasians (HR 0.70, 95% CI 0.59-0.83). The
risk of grade 3-4 aGVHD was signiﬁcantly higher in PBSC
compared to BM alloHCT recipients (HR 1.63, 95% CI 1.20-
2.20), which resulted in higher NRM (HR 1.31, 95% CI 1.04-
1.65) in PBSC compared to BM alloHCT recipients.
Conclusions: Irrespective of graft source, the risk of severe
aGVHDwas lower in Japanese patients, which resulted in the
lower risk of NRM. The risk of severe aGVHD was higher in
the PBSC alloHCT recipients, which resulted in the higher risk
of NRM.14
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Background: Extracorporeal photopheresis (ECP) modulates
host antigen presenting cells implicated in graft versus host
disease (GVHD) development. Incorporation of ECP into a
reduced intensity conditioning (RIC) regimen may prevent
acute (a) and chronic (c) GVHD.
Methods: Data were collected from Tufts Medical Center
BMT and Center for International Bone Marrow Trans-
plantation Registry (CIBMTR) databases. All patients who
received PPTconditioning (ECP on days -6 and -5, Pentostatin
on days -4 and -3, 600 cGy TBI on days -2 and -1) at Tufts
between 10/1999e12/2013 were included. Cyclosporine and
methotrexate were used for GVHD prophylaxis.
Results: 206 pts (56% male) received PPT. Median age was
53 (19-70) with 45% > 55. Median time from diagnosis to
transplant was 17 months (1-180). 59% had matched
related donors. Marrow was the stem cell source in 72%.
8% of transplants were mismatched at 1 antigen. Most
common indications were Acute Myeloid Leukemia (AML)
(35%), Myelodysplastic Syndrome (16%) and Non-Hodgkin
Lymphoma (12%). Of the 73 pts with AML, 33% were in
ﬁrst complete remission (CR1), 18% were in a second or
greater complete remission (CR 2) and 49% had active
disease.ving PPT Conditioning by Diagnosis.
